Director/PDMR Shareholding

RNS Number : 9387Z

Yourgene Health PLC

24 September 2020

 

Yourgene Health plc

("Yourgene" or the "Company")

Director/PDMR Shareholding

Manchester, UK - 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it was notified today of the following directors' share purchases.

The following directors have made the following share purchases on 23 September 2020:

Director	Purchase price	Number of shares purchased	Total number of shares owned following purchase	Percentage of issued share capital held following purchase
Adam Reynolds	17 pence	294,117	6,743,773	0.92%
Lyn Rees	17 pence	294,000	1,037,902	0.14%

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Yourgene Health plc Lyn Rees, Chief Executive Officer		Tel: [phone] [e-mail]
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / James Caithie / Ludovico Lazzaretti
N+1 Singer (Joint Corporate Broker)		Tel: [phone]
Aubrey Powell / Tom Salvesen / George Tzimas
Stifel Nicolaus Europe Limited (Joint Corporate Broker)		Tel: [phone]
Nicholas Moore / Matthew Blawat / Ben Maddison
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone] / Mob: [phone]

About Yourgene Health plc

Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and molecular genetics. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.

Yourgene is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	a) Adam Reynolds b) Lyn Rees
2	Reason for notification
a.	Position/Status	a) Non-executive Chairman b) Chief Executive Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Yourgene Health plc
b.	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 0.1p each ISIN: GB00BN31ZD89
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			a) 17p b) 17p	a) 294,117 b) 294,000
e.	Date of the transaction	23 September 2020
f.	Place of the transaction	London Stock Exchange

 

END

 

 

DSHKXLFLBKLEBBE